Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/28206
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-08-16T12:05:14Z | - |
dc.date.available | 2022-08-16T12:05:14Z | - |
dc.date.issued | 2010-07 | - |
dc.identifier.citation | Başkan, E. B. vd. (2010). "Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis". Journal of the European Academy of Dermatology and Venereology, 24(Supplement 4), 1-1. | en_US |
dc.identifier.issn | 0926-9959 | - |
dc.identifier.uri | https://doi.org/10.3109/09546634.2015.1115813 | - |
dc.identifier.uri | https://www.tandfonline.com/doi/full/10.3109/09546634.2015.1115813 | - |
dc.identifier.uri | http://hdl.handle.net/11452/28206 | - |
dc.description.abstract | Severe forms of psoriasis including erythrodermic or pustular psoriasis, which require a more aggressive therapeutic approach such as phototherapy or systemic therapies, are rarely seen. Systemic toxicity and long-term safety of these agents are serious concerns in children. Objective: We report our experience on the efficacy and safety of cyclosporine A treatment in 22 patients of childhood psoriasis. Methods: We retrospectively analyzed the records of all patients less than 18 years of age treated with systemic cyclosporine A therapy at our clinic between January 2000 and March 2009. Demographic features as well as other relevant data including previous therapies, the dosage and duration of cyclosporine A therapy, response to treatment and side effects were retrieved from the patients’ records. Results: A total of 22 children were treated with systemic cyclosporine A therapy. Seventeen patients were found to be excellent responders. The mean therapeutic dosage of cyclosporine A was 3.47 ± 0.62 mg/kg/day. The mean duration of cyclosporine A therapy was 5.68 ± 3.29 months. The median time to total clearance of the lesions was 4.0 weeks. Conclusion: We conclude that cyclosporine A therapy is equally effective and safe in pediatric psoriasis patients as in adults. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Atopic-dermatitis | en_US |
dc.subject | Dermatology | en_US |
dc.subject | Childhood | en_US |
dc.subject | Ciclosporine A | en_US |
dc.subject | Cyclosporine A | en_US |
dc.subject | Pediatric psoriasis | en_US |
dc.subject | Psoriasis | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Cyclosporine | en_US |
dc.subject.mesh | Dermatologic agents | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Psoriasis | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.title | Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis | en_US |
dc.type | Meeting Abstract | en_US |
dc.identifier.wos | 000279607700003 | tr_TR |
dc.identifier.scopus | 2-s2.0-84949579870 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Deri ve Zührevi Hastalıklar Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-0144-3263 | tr_TR |
dc.identifier.startpage | 1 | tr_TR |
dc.identifier.endpage | 1 | tr_TR |
dc.identifier.volume | 24 | tr_TR |
dc.identifier.issue | Supplement 4 | en_US |
dc.relation.journal | Journal of the European Academy of Dermatology and Venereology | en_US |
dc.contributor.buuauthor | Başkan, Emel Bülbül | - |
dc.contributor.buuauthor | Yazıcı, Serkan | - |
dc.contributor.buuauthor | Tunalı, Şükran | - |
dc.contributor.buuauthor | Sarıcaoğlu, Hayriye | - |
dc.contributor.researcherid | AAH-1388-2021 | tr_TR |
dc.contributor.researcherid | AAH-2459-2021 | tr_TR |
dc.subject.wos | Dermatology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.wos.quartile | Q1 | en_US |
dc.contributor.scopusid | 6602518817 | tr_TR |
dc.contributor.scopusid | 25925620000 | tr_TR |
dc.contributor.scopusid | 7004191748 | tr_TR |
dc.contributor.scopusid | 6603722836 | tr_TR |
dc.subject.scopus | Pustulosis Palmoplantaris; Dermatologists; Diaper Rash | en_US |
dc.subject.emtree | Cyclosporin A | en_US |
dc.subject.emtree | Methotrexate | en_US |
dc.subject.emtree | Prednisolone | en_US |
dc.subject.emtree | Cyclosporin | en_US |
dc.subject.emtree | Dermatological agent | en_US |
dc.subject.emtree | Adolescent | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Child | en_US |
dc.subject.emtree | Childhood psoriasis | en_US |
dc.subject.emtree | Childhood psoriasis | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Drug dose reduction | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug safety | en_US |
dc.subject.emtree | Drug withdrawal | en_US |
dc.subject.emtree | Evening dosage | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Flu like syndrome | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Hypertension | en_US |
dc.subject.emtree | Hypertrichosis | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Medical record | en_US |
dc.subject.emtree | Monotherapy | en_US |
dc.subject.emtree | Morning dosage | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Psoriasis | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Systemic therapy | en_US |
dc.subject.emtree | Treatment duration | en_US |
dc.subject.emtree | Treatment response | en_US |
dc.subject.emtree | Psoriasis | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.